Bioavailability and Boequivalence

Bioavailability and Bioequivalence
General concepts and overview

???WHAT IS IT
???WHY IS IT
???HOW IS IT
.REGULATION VERSUS PHARMACEUTICAL COMP

Generic Drug product: Definition
Same active ingredient (s)
Same strength
Same dosage form
Same route of administration
Same indications
NDA vs. ANDA Review Process
Generic Drug
Original Drug
NDA Requirements ANDA Requirements
1. Chemistry 1. Chemistry
2. Manufacturing 2. Manufacturing
3. Controls 3. Controls
4. Labeling 4. Labeling
5. Testing 5. Testing
6. Animal Studies 6. Bioequivalence Study (In Vivo, In
7. Clinical Studies vitro)
(Bioavailability)
Note: Generic drug applications are termed "abbreviated" because they are generally
not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness.
Instead, generic applicants must scientifically demonstrate that their product is bioequivalent
(i.e., performs in the same manner as the origina; drug).
FDA Definitions Used in Bioequivalence
Determinations
FDA Determinations of Bioequivalence
Main Terms
Pharmaceutical equivalents
Pharmaceutical alternatives
Therapeutic equivalents
Bioavailability
Bioequivalence
Pharmaceutical Equivalents
Drug products are considered pharmaceutical
equivalents if they contain the same active
ingredient(s), have the same dosage form and route of
administration, and are identical in strength or
concentration
Equivalent products contain the same amount of
ingredient in the same dosage form but may differ in
characteristics, such as shape, release mechanisms,
and packaging
Pharmaceutical Alternatives
Drug products are considered pharmaceutical alternatives if
they contain the same therapeutic moiety, are different
salts, esters, or complexes of the same moiety, are different
dosage forms, or are different strengths
Other pharmaceutical alternatives
Different dosage forms and strengths within a single product line by a
single manufacturer
Extended-release formulations when compared with immediate- or
standard-release formulations
Therapeutic Equivalents
Drug products are considered therapeutic equivalents if they
are all of the following
Pharmaceutical equivalents
Bioequivalent
Approved as safe and effective
Adequately labeled
Manufactured in compliance with current Good Manufacturing Practice
regulations
Therapeutic equivalents are expected to have the same
clinical effect and safety profile
Bioavailability
(quantifies ABSORPTION = ?, Reasons for poor F)
The extent and rate at which its active moiety is

delivered from pharmaceutical form and becomes
available in the systemic circulation
Pharmacokinetics
conc. vs time
Conc.(mg/L)
0.0
0 25
Time (h)
?Why do we care about BIOAVAILABILITY
The true dose is not the drug swallowed;
BUT is the drug available to exert its effect.
Dissolution
Absorption
Survive metabolism
May have a drug with very low bioavailability
Dosage form or drug may not dissolve readily
Drug may not be readily pass across biological
membranes (i.e. be absorbed)
Drug may be extensively metabolized during
absorption process (first-pass, gut wall, liver)
Important component of overall variability
Variable bioavailability may produce variable exposure
Rate versus Extent of Absorption
Extent of absorption is reflected by AUC

Rate of absorption, ka, is reflected by Tmax
Both Rate and Extent of absorption affect Cmax
:Leads to 4 possible relative scenarios

(R) Rapid, (E) Complete Absorption
yields a short Tmax, high Cmax, high AUC
(R) Rapid, (E) incomplete absorption
yields a short Tmax, low Cmax, low AUC
(R) Slow, (E) complete absorption
yields a long Tmax, high Cmax, high AUC
(R) Slow, (E) incomplete absorption
yields a long Tmax, low Cmax, low AUC
: FACTORS INFLUENCING BIOAVAILABILITY
Three distinct factors are involved to influencing bioavailability. These are:
1.Pharmaceutical factors:
physicochemical properties of the drug.
1. Particle size
2. Crystalline structure
3. Salt form
Formulation and manufacturing variables.
1.Disintegration and dissolution time
2.Pharmaceutical ingredients
3.Special coatings
4.Nature and type of dosage form
: Patient related factors. 2
Physiologic factors.
1.Variations in pH of GI fluids
2.Gastric emptying rate
3. Intestinal motility
4. Presystemic and first-pass metabolism
5. Age, sex
6. Disease states
Interactions with other substances.
1. Food
2. Fluid volume
3. Other drugs
3. Route of administration:
1.Parentral administration
2.Oral administration
3.Rectal administration
4.Topical administration
Bioequivalence
A comparison of the bioavailability of two or more
drug products.
Two products or formulations containing the same
active ingredient are bioequivalent if their rates
and extents of absorption are the same
Bioequivalence may be demonstrated through in vivo or
in vitro test methods, comparative clinical trials, or
pharmacodynamic studies
Bioequivalence
Regulatory Bioequivalence: An Overview
Self-evident - Biowaivers granted
Solutions Condition- excipients do not alter absorption
(historical data)
Suspensions
Pre-1962 DESI Drugs: In Vivo
SUPAC-IR (1995)
.Chewable, etc evaluation for bio-problem
Dissolution-IR
drugs (TI, PK, P-Chem)
BCS
Conventional Post-1962 Drugs: Generally
(pre-/post approval)
Tablets In Vivo - some exceptions
Capsules ..(IVIVC)
MR Products SUPAC-MR
In VIVO
IVIVC
Bioequivalence: IR Products
Pharmaceutical Equivalent
Products
Reference Test
Possible Differences
, ..Drug particle size
Excipients
Normal healthy subjects
Manufacturing process Crossover design
Equipment Overnight fast
Glass of water
Site of manufacture
CI within 80-125% 90%
. Batch size of Ref. (Cmax & AUC)
Documented Bioequivalence
Therapeutic Equivalence=
.(Note: Generally,Ajaz Hussain,
same FDA spec)
dissolution
FDA Methods to Determine
Bioequivalence
Generic drug manufacturers must demonstrate
that a drug is bioequivalent to a reference drug
product
In order of FDA preference, methods used to
define bioequivalence
Pharmacokinetic studies
Pharmacodynamic studies
Comparative clinical trials
In vitro studies
Pharmacokinetic Studies
Key Measurements
Study Compound AUC
Reference Compound Area under the concentration- time curve
Cmax Cmax
Maximum concentration
A difference of greater than 20% in Cmax or
Concentration
the AUC represents a significant difference

between the study and reference
compounds
Tmax
Time to maximum concentration
AUC
Tmax Time
Comparative Pharmacodynamic Studies
Not recommended when:
active ingredient is absorbed into the systemic
circulation
pharmacokinetic study can be conducted
Local action / no systemic absorption
eg. : Topical Corticosteroid
28 Hanoi, 2006-19-01
Comparative Clinical Studies
Pharmacokinetic profile not possible
Lack of suitable pharmacodynamic endpoint
eg . : (Nasal suspensions)
29 Hanoi, 2006-19-01
Study Designs
-Single-dose, two-way crossover design

- Single-dose, parallel design
-Multiple-dose studies( in case of :
-Drugs too potent/toxic
Extended/modified release products
Crossover vs. Parallel Designs
Crossover design preferred
Intra-subject comparison
Lower variability
Generally fewer subjects required
Parallel design may be useful
Drug with very long half-life
Crossover design not practical
32 Hanoi, 2006-19-01
Disadv. of cross over design
The main problem with the cross over design is :
The carry over effect!?
Fasted vs. Fed Designs
Fasted study design preferred

Minimize variability not attributable to formulation
Better able to detect formulation differences
34 Hanoi, 2006-19-01
Fed Study Designs may be employed when:
Significant gastrointestinal (GI) disturbance caused

by fasted administration
Product labeling restricts administration to fed
state
35 Hanoi, 2006-19-01
When equivalence studies are NOT
necessary (Biowaivers)
Aqueous parenteral solutions

Solutions for oral use ( syrups, elixirs, tinctures & other
soluble forms but not suspensions)
Pdrs for reconstitution as a solution
Otic or ophthalmic aqueous solutions
Topical aqueous solutions
Aqueous nebulizing inhalations or nasal sprays
B. For some products bioequivalence may be
demonstrated by evidence obtained in vitro instead
of in vivo data:
The drug product is in the same dosage form, but in a
different strength, and is proportionally similar in its
active and inactive ingredients to another product by
the same manufacturer that was found to be
bioequivalent.
For high potency drug substances, the same
inactive ingredients are used for all strengths, and
the change in any strength is obtained by altering
the amount of the active ingredients and one or
more of the inactive ingerdients are within the
limits defined by the SUPAC guidances (up to level
II).
Waiver of Bioavailability and
Bioequivalence Studies for Immediate-
Release Solid Oral Dosage Forms Based on
a Biopharmaceutics Classification System
(B.C.S)
BCS Classifications
According to the BCS, drug
substances are classified as
follows:
Class I - High Permeability, High Solubility

Class II - High Permeability, Low Solubility
Class III - Low Permeability, High Solubility
Class IV - Low Permeability, Low Solubility
Solubility
A drug substance is considered highly soluble when
the highest dose strength is soluble in 250 ml or
less of aqueous media over the pH range of 1 - 7.5
(WHO , pH: 1.2 6.8)
Permeability
A drug substance is considered to be highly
permeable when the extent of absorption in
humans is determined to be 90% or more of an
administered dose ( WHO, 85% ).
Conditions for BCS Bio-
waivers
Firms can request waivers of in vivo testing
for Class 1 drug substances
Drug products must meet these
criteria:
Immediate-release solid oral dosage forms
Highly soluble, highly permeable drug
substance
Rapid in vitro dissolution
Note: Waivers not applicable for narrow therapeutic range

therapeutic range (Digoxin, Lithium, phenytoin, warfarin) drugs
A drug product is considered to
be RAPIDLY DISSOLVING when >
85% of the labeled amount of
drug substance dissolves within
30 minutes using USP apparatus
I or II in a volume of < 900 ml
buffer solutions.
BCS Class I: Dissolution
USP Apparatus I (100 rpm) or II (50 rpm)
Three media
0.1 N HCl or SGF USP without enzymes 0.1 N
HCl or SGF USP without enzymes
pH 4.5 buffer pH 4.5 buffer
pH 6.8 buffer or SIF USP without enzymes
NLT 85% dissolves within 30 minutes
Similarity factor (f2) for test (T) v.
reference (R) profile comparisons should
> 50
THANK YOU

Bioavailability and Boequivalence

Uploaded by

Copyright:

Available Formats

Bioavailability and Boequivalence

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Bioavailability and Boequivalence

Uploaded by

Copyright:

Available Formats

Bioavailability and Bioequivalence

General concepts and overview

.REGULATION VERSUS PHARMACEUTICAL COMP

The extent and rate at which its active moiety is

Extent of absorption is reflected by AUC

:Leads to 4 possible relative scenarios

the AUC represents a significant difference

-Single-dose, two-way crossover design

Fasted study design preferred

Significant gastrointestinal (GI) disturbance caused

Aqueous parenteral solutions

Class I - High Permeability, High Solubility

Note: Waivers not applicable for narrow therapeutic range

You might also like